Open AccessDermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
Author(s) -
Bhushan Madke,
Prachi V Gole,
Kumar Prabhash,
Uday Khopkar
Publication year - 2014
Publication title -
indian journal of dermatology/indian journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.395
H-Index - 36
eISSN - 1998-3611
pISSN - 0019-5154
DOI - 10.4103/0019-5154.131398
Subject(s) - medicine , cetuximab , erlotinib , paronychia , gefitinib , epidermal growth factor receptor , dermatology , egfr inhibitors , lung cancer , discontinuation , side effect (computer science) , adverse effect , cancer , oncology , colorectal cancer , computer science , programming language
Epidermal growth factor receptor (EGFR) inhibitor therapy has become the standard treatment for non-small cell lung cancer and head neck malignancy. This class of drug comprises EGFR inhibitors (erlotinib and gefitinib) and monoclonal antibody (cetuximab). Use of this class of drugs has been associated frequently with dermatological side effects termed as PRIDE complex-Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, Dryness due to EGFR inhibitors. We hereby report the cutaneous side effects of EGFR inhibitor therapy in 15 patients of lung and head/neck cancer. The major clinical findings being acneiform eruption and severe xerosis of skin. Management of these dermatological adverse effects rarely requires discontinuation of targeted therapy and can be managed symptomatically.